当前位置: 首页 >> 检索结果
61. Impact of a Chronic Total Occlusion on Outcomes After FFR-Guided PCI or Coronary Bypass Surgery: A FAME 3 Substudy.
作者: Hisao Otsuki.;Kuniaki Takahashi.;Frederik M Zimmermann.;Kreton Mavromatis.;Adel Aminian.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Philip MacCarthy.;Nils Witt.;Yuhei Kobayashi.;Tatsunori Takahashi.;Y Joseph Woo.;Alan C Yeung.;Bernard De Bruyne.;Nico H J Pijls.;William F Fearon.; .
来源: Circ Cardiovasc Interv. 2024年17卷11期e014300页
The clinical impact of a chronic total occlusion (CTO) in patients with 3-vessel coronary artery disease undergoing fractional flow reserve-guided percutaneous coronary intervention (PCI) with current-generation drug-eluting stents or coronary artery bypass grafting (CABG) is unclear.
62. Preventing Allogeneic Stem Cell Transplant-Related Cardiovascular Dysfunction: ALLO-Active Trial.
作者: Hayley T Dillon.;Nicholas J Saner.;Tegan Ilsley.;David S Kliman.;Stephen J Foulkes.;Christian J Brakenridge.;Andrew Spencer.;Sharon Avery.;Piet Claus.;David W Dunstan.;Robin M Daly.;Steve F Fraser.;Neville Owen.;Brigid M Lynch.;Bronwyn A Kingwell.;Andre La Gerche.;Erin J Howden.
来源: Circulation. 2025年151卷4期292-308页
Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can be complicated by cardiac dysfunction and exercise intolerance impacting quality of life and longevity. We conducted a randomized controlled trial testing whether a multicomponent activity intervention could attenuate reductions in cardiorespiratory fitness and exercise cardiac function (co-primary end points) in adults undergoing allo-SCT.
63. Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial.
作者: Wissam A Jaber.;Carin F Gonsalves.;Stefan Stortecky.;Samuel Horr.;Orestis Pappas.;Ripal T Gandhi.;Keith Pereira.;Jay Giri.;Sameer J Khandhar.;Khawaja Afzal Ammar.;David M Lasorda.;Brian Stegman.;Lucas Busch.;David J Dexter.;Ezana M Azene.;Nikhil Daga.;Fakhir Elmasri.;Chandra R Kunavarapu.;Mark E Rea.;Joseph S Rossi.;Joseph Campbell.;Jonathan Lindquist.;Adam Raskin.;Jason C Smith.;Thomas M Tamlyn.;Gabriel A Hernandez.;Parth Rali.;Torrey R Schmidt.;Jeffrey T Bruckel.;Juan C Camacho.;Jun Li.;Samy Selim.;Catalin Toma.;Sukhdeep Singh Basra.;Brian A Bergmark.;Bhavraj Khalsa.;David M Zlotnick.;Jordan Castle.;David J O'Connor.;C Michael Gibson.; .
来源: Circulation. 2025年151卷5期260-273页
There are a lack of randomized controlled trial data comparing outcomes of different catheter-based interventions for intermediate-risk pulmonary embolism.
64. Fractional Flow Reserve and Instantaneous Wave-Free Ratio as Predictors of the Placebo-Controlled Response to Percutaneous Coronary Intervention in Stable Coronary Artery Disease.
作者: Michael J Foley.;Christopher A Rajkumar.;Fiyyaz Ahmed-Jushuf.;Florentina Simader.;Shayna Chotai.;Henry Seligman.;Krzysztof Macierzanka.;John R Davies.;Thomas R Keeble.;Peter O'Kane.;Peter Haworth.;Helen Routledge.;Tushar Kotecha.;Gerald Clesham.;Rupert Williams.;Jehangir Din.;Sukhjinder S Nijjer.;Nick Curzen.;Manas Sinha.;Ricardo Petraco.;James Spratt.;Sayan Sen.;Graham D Cole.;Frank E Harrell.;James P Howard.;Darrel P Francis.;Matthew J Shun-Shin.;Rasha Al-Lamee.; .
来源: Circulation. 2025年151卷3期202-214页
ORBITA-2 (the Placebo-Controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina) provided evidence for the role of percutaneous coronary intervention (PCI) for angina relief in stable coronary artery disease. Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are often used to guide PCI; however, their ability to predict placebo-controlled angina improvement is unknown.
65. Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.
作者: Elric Zweck.;Christian Hassager.;Rasmus P Beske.;Lisette O Jensen.;Hans Eiskjær.;Norman Mangner.;Amin Polzin.;P Christian Schulze.;Carsten Skurk.;Peter Nordbeck.;Peter Clemmensen.;Vasileios Panoulas.;Sebastian Zimmer.;Andreas Schäfer.;Malte Kelm.;Thomas Engstrøm.;Lene Holmvang.;Anders Junker.;Henrik Schmidt.;Christian J Terkelsen.;Axel Linke.;Ralf Westenfeld.;Jacob E Møller.; .
来源: Circulation. 2024年150卷25期1990-2003页
In DanGer Shock (the Danish-German Cardiogenic Shock trial), use of a microaxial flow pump (mAFP) in patients with ST-segment-elevation myocardial infarction-related cardiogenic shock led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed.
66. Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
作者: Li Shen.;Pooja Dewan.;João Pedro Ferreira.;Jonathan W Cunningham.;Pardeep S Jhund.;Inder S Anand.;Alvin Chandra.;Lu-May Chiang.;Brian Claggett.;Akshay S Desai.;Jianjian Gong.;Carolyn S P Lam.;Martin P Lefkowitz.;Aldo P Maggioni.;Felipe Martinez.;Milton Packer.;Margaret M Redfield.;Jean L Rouleau.;Dirk J van Veldhuisen.;Faiez Zannad.;Michael R Zile.;Scott D Solomon.;John J V McMurray.
来源: Circulation. 2024年150卷24期1913-1927页
Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood.
67. Three-Year Outcomes Following TAVR in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients.
作者: Thomas Modine.;Didier Tchétché.;Nicolas M Van Mieghem.;G Michael Deeb.;Stanley J Chetcuti.;Steven J Yakubov.;Paul Sorajja.;Hemal Gada.;Mubashir Mumtaz.;Basel Ramlawi.;Tanvir Bajwa.;John Crouch.;Paul S Teirstein.;Neal S Kleiman.;Ayman Iskander.;Rodrigo Bagur.;Michael W A Chu.;Pierre Berthoumieu.;Arnaud Sudre.;Rik Adrichem.;Saki Ito.;Jian Huang.;Jeffrey J Popma.;John K Forrest.;Michael J Reardon.
来源: Circ Cardiovasc Interv. 2024年17卷11期e014018页
Transcatheter aortic valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis, but data are limited on younger, low-risk patients. This analysis compares outcomes in low-surgical-risk patients aged <75 years receiving TAVR versus surgery.
68. Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial.
作者: Robert A Byrne.;Róisín Colleran.;J J Coughlan.;Rajiv Jauhar.;Luc Maillard.;Axel De Labriolle.;Michael Maeng.;Charles Croft.;Michael Brunner.;David Leistner.;Bernhard Zrenner.;Marc Kollum.;Karl-Ludwig Laugwitz.;Erion Xhepa.;Katharina Mayer.;Shqipdona Lahu.;Michael Joner.;Ajay Kirtane.;Roxana Mehran.;Mark Barakat.;Philip Urban.;Donald E Cutlip.;Adnan Kastrati.; .
来源: Circ Cardiovasc Interv. 2024年17卷10期e013735页
Patients with an indication for oral anticoagulation who undergo percutaneous coronary intervention require a combination of oral anticoagulation and antiplatelet therapy. The use of a coronary stent with a thromboresistant and pro-healing coating may allow an abbreviated duration of dual antiplatelet therapy (DAPT) without an increase in the risk of thromboembolic events.
69. Ablation Strategies for Repeat Procedures in Atrial Fibrillation Recurrences Despite Durable Pulmonary Vein Isolation: The Prospective Randomized ASTRO AF Multicenter Trial.
作者: Boris Schmidt.;Stefano Bordignon.;Andreas Metzner.;Philipp Sommer.;Daniel Steven.;Tilmann Dahme.;Matthias Busch.;Roland Richard Tilz.;David Schaack.;Andreas Rillig.;Christian Sohns.;Arian Sultan.;Karolina Weinmann-Emhardt.;Astrid Hummel.;Julia Vogler.;Thomas Fink.;Jakob Lueker.;Alexander Pott.;Christian Heeger.;K R Julian Chun.
来源: Circulation. 2024年150卷25期2007-2018页
Ablation strategies for patients with symptomatic atrial fibrillation and isolated pulmonary veins vary and their effects on arrhythmia recurrence remain unclear. A prospective randomized German multicenter trial sought to compare 2 ablation strategies in this patient cohort.
70. Comparison of Ultrathin- Versus Thin-Strut Stents in Patients With High Bleeding Risk PCI: Results From the COMPARE 60/80 HBR Trial: An Open-Label, Randomized, Controlled Trial.
作者: Pieter C Smits.;Pim A L Tonino.;Sjoerd H Hofma.;Jan-Peter van Kuijk.;Fabrizio Spano.;Amar Al Mafragi.;Ron Pisters.;Jawed Polad.;Kris Bogaerts.;Rohit M Oemrawsingh.;Valeria Paradies.
来源: Circ Cardiovasc Interv. 2024年17卷10期e014042页
No randomized data exist on ultrathin-strut stents in patients at high bleeding risk (HBR) undergoing an abbreviated dual antiplatelet therapy after coronary stenting. The aim of this study was to compare the safety and effectiveness of the ultrathin-strut biodegradable-polymer sirolimus-eluting Supraflex Cruz stent with the thin-strut biodegradable-polymer sirolimus-eluting Ultimaster Tansei stent in patients at HBR with abbreviated dual antiplatelet therapy after stenting.
71. Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF.
作者: Misato Chimura.;Mark C Petrie.;Morten Schou.;Felipe A Martinez.;Alasdair D Henderson.;Brian L Claggett.;Akshay S Desai.;Peter Kolkhof.;Prabhakar Viswanathan.;Andrea Lage.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Katja Rohwedder.;Katharina Mueller.;Adriaan A Voors.;Faiez Zannad.;Bertram Pitt.;Muthiah Vaduganathan.;Pardeep S Jhund.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2024年17卷11期e012437页
Finerenone improves outcomes in patients with heart failure and mildly reduced or preserved ejection fraction. It is important to understand the efficacy and safety of finerenone in these patients according to age.
72. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the FINEARTS-HF Trial.
作者: Kieran F Docherty.;Alasdair D Henderson.;Pardeep S Jhund.;Brian L Claggett.;Akshay S Desai.;Katharina Mueller.;Prabhakar Viswanathan.;Andrea Scalise.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Faiez Zannad.;Bertram Pitt.;Muthiah Vaduganathan.;Scott D Solomon.;John J V McMurray.
来源: Circulation. 2025年151卷1期45-58页
The effects of treatments for heart failure (HF) may vary among patients according to left ventricular ejection fraction (LVEF). In FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure), the nonsteroidal mineralocorticoid receptor antagonist finerenone reduced the risk of cardiovascular death and total worsening HF events in patients with HF with mildly reduced or preserved ejection fraction. We examined the effect of finerenone according to LVEF in FINEARTS-HF.
73. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
作者: Muthiah Vaduganathan.;Brian L Claggett.;Ian J Kulac.;Zi Michael Miao.;Akshay S Desai.;Pardeep S Jhund.;Alasdair D Henderson.;Meike Brinker.;James Lay-Flurrie.;Prabhakar Viswanathan.;Markus Florian Scheerer.;Andrea Lage.;Carolyn S P Lam.;Michele Senni.;Sanjiv J Shah.;Adriaan A Voors.;Faiez Zannad.;Bertram Pitt.;John J V McMurray.;Scott D Solomon.
来源: Circulation. 2025年151卷2期149-158页
Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and the nonsteroidal mineralocorticoid receptor antagonist finerenone have both been shown to reduce the risk of cardiovascular events in this population, but the effects of their combined use are not known.
74. Prognostic Value of Murray Law-Based QFR (μQFR)-Guided Virtual PCI in Patients With Physiological Ischemia.
作者: Lianglong Chen.;Yuanming Yan.;Jiaxin Zhong.;Ping Chen.;Wei Chen.;Chaoxiang Xu.;Long Chen.;Shengxian Tu.;Yukun Luo.
来源: Circ Cardiovasc Interv. 2024年17卷10期e014362页
Quantitative flow ratio (QFR)-based virtual percutaneous coronary intervention (PCI) is associated with improved post-PCI physiological results. Murray law-based QFR (μQFR) is a new method for physiological assessment that has higher feasibility and efficiency. The purpose of this study was to investigate the performance of μQFR-guided virtual PCI in improving post-PCI outcomes.
75. Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial.
作者: Robert Shaddy.;Michael Burch.;Paul F Kantor.;Susan Solar-Yohay.;Tania Garito.;Sijia Zhang.;Michele Kocun.;Chad Mao.;Antoinette Cilliers.;Xu Wang.;Charles Canter.;Joseph Rossano.;Gonzalo Wallis.;Jondavid Menteer.;Linda Daou.;Jacek Kusa.;Kursat Tokel.;Daniel Dilber.;Zhuoming Xu.;Tingting Xiao.;Nancy Halnon.;Kevin P Daly.;Matthew J Bock.;Warren Zuckerman.;Tajinder P Singh.;Manisha Chakrabarti.;Aviva Levitas.;Michele Senni.;Giorgia Grutter.;Gi Beom Kim.;Jinyoung Song.;Hyoung Doo Lee.;Ching Kit Chen.;Joan Sanchez-de-Toledo.;Yuk Law.;Suthep Wanitkun.;Yanqin Cui.;Rui Anjos.;Timur Mese.;Damien Bonnet.; .
来源: Circulation. 2024年150卷22期1756-1766页
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD).
76. Effect of Delayed Remote Ischemic Preconditioning on Acute Kidney Injury and Outcomes in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial.
作者: Ping Jia.;Qiang Ji.;Zhouping Zou.;Qi Zeng.;Ting Ren.;Weize Chen.;Zhixin Yan.;Daoqi Shen.;Yang Li.;Fangyuan Peng.;Ying Su.;Jiarui Xu.;Bo Shen.;Zhe Luo.;Chunsheng Wang.;Xiaoqiang Ding.
来源: Circulation. 2024年150卷17期1366-1376页
Remote ischemic preconditioning (RIPC) has 2 time windows for organ protection: acute and delayed. Previous studies have mainly focused on the organoprotective effects of acute RIPC. We aimed to determine whether delayed RIPC can reduce the occurrence of acute kidney injury (AKI) and postoperative complications in patients undergoing cardiac surgery.
77. Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.
作者: Gregg W Stone.;JoAnn Lindenfeld.;Josep Rodés-Cabau.;Stefan D Anker.;Michael R Zile.;Saibal Kar.;Richard Holcomb.;Michael P Pfeiffer.;Antoni Bayes-Genis.;Jeroen J Bax.;Alan J Bank.;Maria Rosa Costanzo.;Stefan Verheye.;Ariel Roguin.;Gerasimos Filippatos.;Julio Núñez.;Elizabeth C Lee.;Michal Laufer-Perl.;Gil Moravsky.;Sheldon E Litwin.;Edgard Prihadi.;Hemal Gada.;Eugene S Chung.;Matthew J Price.;Vinay Thohan.;Dimitry Schewel.;Sachin Kumar.;Stephan Kische.;Kevin S Shah.;Daniel J Donovan.;Yiran Zhang.;Neal L Eigler.;William T Abraham.; .
来源: Circulation. 2024年150卷24期1931-1943页
An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis.
78. International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights From the ISCHEMIA Trial.
作者: Nobuhiro Ikemura.;John A Spertus.;Dan Nguyen.;Zhuxuan Fu.;Philip G Jones.;Harmony R Reynolds.;Sripal Bangalore.;Balram Bhargava.;Roxy Senior.;Ahmed Elghamaz.;Shaun G Goodman.;Renato D Lopes.;Radoslaw Pracoń.;José López-Sendón.;Aldo P Maggioni.;Shun Kohsaka.;Gregory A Roth.;Harvey D White.;Kreton Mavromatis.;William E Boden.;Fatima Rodriguez.;Judith S Hochman.;David J Maron.; .
来源: Circ Cardiovasc Qual Outcomes. 2024年17卷10期e010534页
The ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) demonstrated greater health status benefits with an initial invasive strategy, as compared with a conservative one, for patients with chronic coronary disease and moderate or severe ischemia. Whether these benefits vary globally is important to understand to support global adoption of the results.
79. CCTA-Guided Invasive Coronary Angiography in Patients With CABG: A Multicenter, Randomized Study.
作者: Grigorios Tsigkas.;Fotios Toulgaridis.;Anastasios Apostolos.;Andreas Kalogeropoulos.;Grigoris V Karamasis.;Georgios Vasilagkos.;Loukas Pappas.;Konstantinos Toutouzas.;Konstantinos Tsioufis.;Panagiotis Korkonikitas.;Ioannis Tsiafoutis.;Michalis Hamilos.;Antonios Ziakas.;Ioannis Kanakakis.;Athanasios Moulias.;Petros Zampakis.;Periklis Davlouros.
来源: Circ Cardiovasc Interv. 2024年17卷9期e014045页
Coronary computed tomography angiography (CCTA) in patients with post-coronary artery bypass graft (CABG) has a high diagnostic accuracy for visualization of grafts. Invasive coronary angiography (ICA) in patients with CABG is associated with increased procedural time, contrast agent administration, radiation exposure, and complications, compared with non-CABG patients. The aim of this multicenter, randomized controlled trial was to compare the strategy of CCTA-guided ICA versus classic ICA in patients with prior CABG.
80. Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial.
作者: William F McIntyre.;Alexander P Benz.;Jeff S Healey.;Stuart J Connolly.;Mu Yang.;Shun Fu Lee.;Thalia S Field.;Marco Alings.;J Benezet-Mazuecos.;Giuseppe Boriani.;J Cosedis Nielsen.;Michael R Gold.;Francesco Pergolini.;Taya V Glotzer.;Christopher B Granger.;Renato D Lopes.
来源: Circulation. 2024年150卷22期1747-1755页
In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclinical atrial fibrillation (SCAF). Clinical guidelines recommend considering SCAF episode duration when deciding whether to prescribe oral anticoagulation for this population.
|